Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

By: TheNewswire.com

May 03, 2023 at 14:20 PM EDT

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

More News

AMD to $300 Looks Easy—Here’s Why $500 Could Be Next ↗

Today 12:03 EST

Via MarketBeat

$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You ↗

Today 11:23 EST

Via MarketBeat

4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive ↗

Today 10:15 EST

Via MarketBeat

Oklo’s Meltdown Is Over: A Robust Rebound Lies Ahead ↗

Today 9:22 EST

Via MarketBeat

3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming ↗

Today 8:19 EST

Via MarketBeat

Recent Quotes

Symbol	Price	Change (%)
AMZN	238.50	-5.69 (-2.33%)
AAPL	273.20	-0.27 (-0.10%)
AMD	246.87	-12.02 (-4.64%)
BAC	53.20	-0.91 (-1.67%)
GOOG	279.00	-8.44 (-2.93%)
META	603.93	-5.08 (-0.83%)
MSFT	505.89	-5.25 (-1.03%)
NVDA	184.42	-9.38 (-4.84%)
ORCL	216.56	-10.43 (-4.59%)
TSLA	398.20	-32.40 (-7.52%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.